FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number:    

 
 
CIBMTR Recipient ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type: (Check all that apply) 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type: (Check all that apply) 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 

  
gfedcb

If this is a report of a second or subsequent transplant, check here and continue with question 72.

 
 
1  What was the date of pathologic diagnosis of the central nervous system (CNS) tumor? __ __ __ __ - __ __- __ __  

 
 
2  What was the primary disease for which the HSCT was performed?   

 
 
3  Specify other PNET:    

 
 
4  Specify other high-grade glial tumor:    

 
 
5  Specify pathologic diagnosis from Astrocytomas or Other tumors:    

 
 
6  What was the extent of the CNS tumor at diagnosis?   

 
 

7  What was the primary CNS tumor site at diagnosis?

    
 nmlkji

brainstem (medulla/pons/midbrain)  

 nmlkji
cerebral hemisphere  

 nmlkji
cerebellar hemisphere/vermis  

 nmlkji
optic chiasma/hypothalamus/suprasellar area  

 nmlkji
spinal cord  

 nmlkji
thalamus/basal ganglia/corpus callosum  

 nmlkji
extra-CNS primary site  

 
 
8  Specify site:    

 
 

9  Does the recipient have a history of co-existing phakomatosis?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  Key Fields 

Disease Assessment at Diagnosis Questions: 1 - 71

Form 2025 R2.0: Central Nervous System Tumor Pre-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2025 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 7



 
 

10  Specify the co-existing phakomatosis:

    
 nmlkji

cerebroretinal angiomatosis (Von Hippel-Lindau disease)  

 nmlkji
encephalotrigeminal angiomatosis (Sturge-Weber syndrome)  

 nmlkji
Neurofibromatosis type 1  

 nmlkji
neurofibromatosis type 2  

 nmlkji
tuberous sclerosis (Bourneville disease)  

 nmlkji
other phakimatosis  

 
 
11  Specify phakomatosis:    

 
 

12  At the time of diagnosis, did the recipient have a family history of cancer in first degree relatives under 40 years of age?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 

Specify the cancer(s) present in first degree relatives: 
 

13  Basal cell carcinoma

    
 nmlkji

yes  
 nmlkji

no  

 
 

14  Brain tumors

    
 nmlkji

yes  
 nmlkji

no  

 
 

15  Breast cancer

    
 nmlkji

yes  
 nmlkji

no  

 
 

16  Colo-rectal carcinoma

    
 nmlkji

yes  
 nmlkji

no  

 
 

17  Malignant nerve sheath tumors

    
 nmlkji

yes  
 nmlkji

no  

 
 

18  Neurofibromas

    
 nmlkji

yes  
 nmlkji

no  

 
 

19  Soft tissue sarcoma

    
 nmlkji

yes  
 nmlkji

no  

 
 

20  Other cancer

    
 nmlkji

yes  
 nmlkji

no  

 
 
21  Specify cancer:    

 
 

22  Was therapy given between diagnosis and the start of the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  

 

Line of Therapy 
 
23  Date therapy started: __ __ __ __ - __ __- __ __  

 
 
24  Date therapy stopped: __ __ __ __ - __ __- __ __  

 
 

25  Systemic Therapy:

    
 nmlkji

yes  
 nmlkji

no  

  
 
26  Number of cycles    

 
  

gfedcb
Number of cycles unknown/not applicable

  Pre-HSCT Treatment for CNS Tumor (1) Questions: 23 - 71 

Form 2025 R2.0: Central Nervous System Tumor Pre-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2025 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 7



 

Treatment: 
 

27  bleomycin (BLM, Blenoxane)

    
 nmlkji

yes  
 nmlkji

no  

 
 

28  carboplatin (Paraplatin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

29  Cisplatin (Platinol, CDDP)

    
 nmlkji

yes  
 nmlkji

no  

 
 

30  Corticosteroids

    
 nmlkji

yes  
 nmlkji

no  

 
 

31  Cyclophosphamide (Cytoxan)

    
 nmlkji

yes  
 nmlkji

no  

 
 

32  Etoposide (VP-16, VePesid)

    
 nmlkji

yes  
 nmlkji

no  

 
 

33  Ifosfamide (Ifex)

    
 nmlkji

yes  
 nmlkji

no  

 
 

34  melphalan (L-PAM, Alkeran)

    
 nmlkji

yes  
 nmlkji

no  

 
 

35  methotrexate (MTX, Folex)

    
 nmlkji

yes  
 nmlkji

no  

 
 

36  nitrosourea (carmustine)

    
 nmlkji

yes  
 nmlkji

no  

 
 

37  procarbazine (Matulane)

    
 nmlkji

yes  
 nmlkji

no  

 
 

38  temozolomide (Temodar)

    
 nmlkji

yes  
 nmlkji

no  

 
 

39  thiotepa (Thioplex)

    
 nmlkji

yes  
 nmlkji

no  

 
 

40  topotecan (Hycamtin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

41  Vincristine (VCR, Oncovin)

    
 nmlkji

yes  
 nmlkji

no  

 
 

42  other therapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
43  Specify other therapy:    

 
 

44  Hematopoietic growth factor?

    
 nmlkji

yes  
 nmlkji

no  

 
 

45  Number of chemo cycles used with hematopoietic growth factor:

    
 nmlkji

<5  
 nmlkji

>=5  
 nmlkji

Unknown  

Form 2025 R2.0: Central Nervous System Tumor Pre-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2025 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 7



 
 

46  Radiation Therapy:

    
 nmlkji

yes  
 nmlkji

no  

 
 

47  Whole brain

    
 nmlkji

yes  
 nmlkji

no  

 
 
48  Specify total dose:    cGy (rads) 

 
 

49  Local cranial

    
 nmlkji

yes  
 nmlkji

no  

 
 
50  Specify total dose:    cGy (rads) 

 
 

51  Craniospinal

    
 nmlkji

yes  
 nmlkji

no  

 
 
52  Specify total dose:    cGy (rads) 

 
 

53  Gamma knife / radiosurgery

    
 nmlkji

yes  
 nmlkji

no  

 
 
54  Specify total dose:    cGy (rads) 

 
 

55  Interstitial irradiation / brachytherapy

    
 nmlkji

yes  
 nmlkji

no  

 
 
56  Specify total dose:    cGy (rads) 

 
 

57  Radioactive instillation

    
 nmlkji

yes  
 nmlkji

no  

 
 
58  Specify total dose:    cGy (rads) 

 
 

59  Local spinal

    
 nmlkji

yes  
 nmlkji

no  

 
 
60  Specify total dose:    cGy (rads) 

 
 

61  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
62  Specify other site:    

 
 
63  Specify total dose:    cGy (rads) 

 
 

64  Fractionation schedule

    
 nmlkji

single  
 nmlkji

single daily  
 nmlkji

multiple daily  
 nmlkji

other schedule  

 
 

65  Surgical Biopsy/Resection:

    
 nmlkji

yes  
 nmlkji

no  

 
 
66  Type of surgery   

 
 
67  Size of residual tumor after surgery (see codes below)   

 
 

68  Was this line of therapy given for stem cell priming?

    
 nmlkji

yes  
 nmlkji

no  

 
 
69  Best Response to Line of Therapy   

 
 
70  Date response evaluated: __ __ __ __ - __ __- __ __  

 
 

71  Did patient relapse/progress following this line of therapy?

    
 nmlkji

yes  
 nmlkji

no  

Form 2025 R2.0: Central Nervous System Tumor Pre-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2025 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 7



 

Specify all sites of disease involvement between diagnosis and the start of the preparative regimen:  
 

72  Cerebrospinal fluid

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

73  Extraneural

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

74  Distant intracranial parenchymal

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

75  Intracranial leptomeningeal

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

76  Spinal leptomeningeal

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

77  Local primary site

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

78  Other site:

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 
79  Specify other site:    

 
 

80  Was CNS tumor present in the recipient's bone at any time between diagnosis and the preparative regimen?

    
 nmlkji

yes  
 nmlkji

no  

 
 

81  Bone scan

    
 nmlkji

yes  
 nmlkji

no  

  
 
82  Date of bone scan: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date bone scan unknown

 
 

83  Was the bone scan positive for CNS tumor?

    
 nmlkji

yes  
 nmlkji

no  

 
 

84  MRI

    
 nmlkji

yes  
 nmlkji

no  

  
 
85  Date of MRI: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date of MRI unkown

 
 

86  Was the MRI postive for CNS tumor?

    
 nmlkji

yes  
 nmlkji

no  

 
 

87  Was a bone marrow aspirate / biopsy performed with in 30 days of the preparative regimen?

    
 nmlkji

Yes  
 nmlkji

No  
 nmlkji

Not known  

  
 
88  Specify the date the bone marrow biopsy was performed: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date the bone marrow biopsy performed unknown

 
 

89  Was any tumor present in the biopsy?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the test(s) used: 
 

90  Cytogenetics

    
 nmlkji

yes  
 nmlkji

no  

  Disease Involvement Between Diagnosis and the Preparative Regimen Questions: 72 - 86

  Bone Marrow Aspirate / Biopsy Performed Questions: 87 - 102

Form 2025 R2.0: Central Nervous System Tumor Pre-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2025 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 7



 
 

91  Specify cytogenetic results:

    
 nmlkji

positive for tumor involvement  

 nmlkji
Negative  

 
 

92  Immunohistochemistry

    
 nmlkji

yes  
 nmlkji

no  

 
 

93  Specify immunohistochemistry results:

    
 nmlkji

positive for tumor involvement  

 nmlkji
Negative  

 
 

94  Routine histopathology

    
 nmlkji

yes  
 nmlkji

no  

 
 

95  Specify histopathology results:

    
 nmlkji

positive for tumor involvement  

 nmlkji
Negative  

 
 

96  Other test method

    
 nmlkji

yes  
 nmlkji

no  

 
 
97  Specify other test:    

 
 

98  Specify test results:

    
 nmlkji

positive for tumor involvement  

 nmlkji
Negative  

 
 

99  Was a bone scan performed within 30 days of the preparative regimen (other than that reported at question 80)?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

  
 
100  Date of bone scan: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date unknown

 
 

101  Was the bone scan positive for CNS tumor?

    
 nmlkji

yes  
 nmlkji

no  

 
102  What was the sensitivity of the CNS tumor to chemotherapy prior to the preparative regimen?(Report response to last chemotherapy given prior to HSCT; chemotherapy must be >= 

two cycles of treatment given < 6 months prior to the preparative regimen.) 

    
 nmlkji
sensitive: ≥ 50% reduction in bidimensional diameter of all disease sites with no new sites of disease (CR, CRU, PR)  

 nmlkji
resistant: <50% reduction in diameter of all disease sites or development of new disease sites (NR, PD)  

 nmlkji
untreated, or treated > 6 months prior to transplant  

 nmlkji
not assessed, or chemotherapy < 2 cycles  

 
 
103  What was the disease status immediately prior to the preparative regimen? (see CNS disease status definitions on page 4)   

 

Specify all sites of residual disease: 
 

104  Cerebrospinal fluid (CSF)

    
 nmlkji

yes  
 nmlkji

no  

 
 

105  Extraneural

    
 nmlkji

yes  
 nmlkji

no  

  Disease Status at the Last Assessment Prior to the Preparative Regimen Questions: 103 - 112

Form 2025 R2.0: Central Nervous System Tumor Pre-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2025 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 7



 
 

106  Distant intracranial parenchymal

    
 nmlkji

yes  
 nmlkji

no  

 
 

107  Intracranial leptomeningeal

    
 nmlkji

yes  
 nmlkji

no  

 
 

108  Spinal leptomeningeal

    
 nmlkji

yes  
 nmlkji

no  

 
 

109  Local primary site

    
 nmlkji

yes  
 nmlkji

no  

 
 

110  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
111  Specify other site:    

 
 
112  Date of the most recent assessment for disease status prior to the preparative regimen: __ __ __ __ - __ __- __ __  

  
 
First Name:    

 
Last Name:    

  
 
Phone number:    

 
Fax number:    

 
 
E-mail address:    

Form 2025 R2.0: Central Nervous System Tumor Pre-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2025 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 7